<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650975</url>
  </required_header>
  <id_info>
    <org_study_id>D001747-01</org_study_id>
    <nct_id>NCT00650975</nct_id>
  </id_info>
  <brief_title>ThromboAblation in Acute Myocardial Infarction</brief_title>
  <acronym>TAAMI</acronym>
  <official_title>ThromboAblation in Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KCRI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KCRI</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Assess whether excimer laser coronary atherectomy (ELCA) before direct infarct-related&#xD;
           artery (IRA) stenting results in improved reperfusion success in patients presenting&#xD;
           with acute ST wave elevation myocardial infarction (STEMI) and angiographically evident&#xD;
           thrombus.&#xD;
&#xD;
        2. Validate an ELCA technique for the treatment of STEMI, at high-volume centers&#xD;
           experienced in the treatment of acute myocardial infarction (AMI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment rate.&#xD;
  </why_stopped>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Blush Grade 3 (MBG3) ST-Resolution MACE</measure>
    <time_frame>60 minutes - 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>ST Elevation Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>ELCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laser Thromboablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTCA (Direct Stenting)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Thromboablation</intervention_name>
    <description>Laser Thromboablation using the Spectranetics CVX-300® excimer laser system</description>
    <arm_group_label>ELCA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTCA (Direct Stenting)</intervention_name>
    <description>Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use</description>
    <arm_group_label>PTCA</arm_group_label>
    <other_name>PCI</other_name>
    <other_name>Direct Stenting</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Electrocardiographic inclusion criteria: (baseline 12-lead ECG recorded at 25 mm/second&#xD;
        upon arrival at investigational center)&#xD;
&#xD;
          -  STEMI within 12 hours of symptom onset, with ≥ 2 mm ST segment elevation in two or&#xD;
             more leads and minimum ≥ 3 mm ST segment elevation in one lead.&#xD;
&#xD;
        Angiographic inclusion criteria after crossing with guidewire:&#xD;
&#xD;
          -  IRA is a native coronary artery; and,&#xD;
&#xD;
          -  Reference vessel diameter 2.5 - 4.0 mm; and,&#xD;
&#xD;
          -  TIMI 0 or 1 flow with any TIMI thrombus grade; or,&#xD;
&#xD;
          -  TIMI 2 or 3 flow with TIMI thrombus grade 3 or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unwilling or unable to give informed consent&#xD;
&#xD;
          -  Previous MI in the distribution of the current IRA&#xD;
&#xD;
          -  Previous CABG&#xD;
&#xD;
          -  Contraindications to PCI&#xD;
&#xD;
               -  allergy(s) to intended study medications&#xD;
&#xD;
               -  contraindicated for stent implantation&#xD;
&#xD;
          -  Active bleeding or coagulopathy&#xD;
&#xD;
          -  Patient in cardiogenic shock (&lt;90mmHg SBP and/or requiring IABP or vasopressors)&#xD;
&#xD;
          -  Known left ventricular ejection fraction (EF) &lt;30%&#xD;
&#xD;
          -  Fibrinolytic administered before PCI&#xD;
&#xD;
          -  Renal insufficiency (creatinine &gt;2.0mg/dl)&#xD;
&#xD;
          -  Current vitamin K antagonist therapy or known INR &gt;1.5&#xD;
&#xD;
          -  Known thrombocytopenia - platelets &lt;100,000 cell count&#xD;
&#xD;
          -  Patient has Left Bundle Branch Block (LBBB) or pacemaker rhythm&#xD;
&#xD;
          -  Known history of hemorrhagic stroke (CVA or TIA) &lt;2 years before screening&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Current cancer disease&#xD;
&#xD;
          -  Comorbidity where survival is anticipated to be &lt;1 year.&#xD;
&#xD;
          -  No future patient cooperation expected&#xD;
&#xD;
          -  Patient is participating in another clinical study&#xD;
&#xD;
          -  Patient &lt;18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dariusz Dudek, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Haemodynamics and Angiocardiography Medical College Jagiellonian University University Hospital in Krakow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gornoslaskie Centrum Medyczne 3rd Dept of Cardiology</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University College of Medicine, Institute of Cardiology John Paul II Hospital</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Haemodynamics and Angiocardiography Medical College Jagiellonian University University Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital No. 1 1st Dept. of Cardiology</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology Hemodynamics dept., Cardiac Catheterization Laboratory</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>William Kerker, Sr. Manager, Clinical Applications Research</name_title>
    <organization>Spectranetics Corporation</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>Laser</keyword>
  <keyword>Thrombus</keyword>
  <keyword>Thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

